Craven House Capital - Craven House increases stake in LMFA

Craven House Capital

30/08/2019 17:18

RNS Number : 7853K

Craven House Capital PLC

30 August 2019

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Craven House Capital plc

 

("Craven House" or the "Company")

 

Craven House increases stake in LMFA

 

The Company confirms that it has acquired a further 44,366 shares in LM Funding America Inc. ("LMFA"), taking its total holding to 818,675 shares representing 26% of the issued share capital of LMFA.

 

As announced on 17 January 2019, the Company issued a convertible promissory note for the balance of the consideration in relation to its sale of IIU Inc., to LMFA (the "Transaction") for approximately $3.6 million ("Convertible Note"). The Convertible Note is due and payable 360 days following the completion of the Transaction. The Convertible Note is to be redeemed at Craven House's option in cash or, subject to LMFA shareholder approval in a general meeting, in common stock of LMFA at a conversion price of $2.41 per share.  The Convertible Note will be due for redemption at any time on or after the first meeting of shareholders of LMFA to occur in 2019.

 

If the entire principal value of the Convertible Note is converted into shares, Craven House will obtain 1,486,714 shares in LMFA taking its holding to 2,305,389 shares representing 49.9% of the issued share capital based on 4,620,975 LFMA common shares being in issue on conversion.



~ Ends ~

 

 

For further information please contact:

 

Craven House Capital Plc
Mark Pajak
www.Cravenhousecapital.com
Tel: 0203 286 8130
SI Capital
Broker
Nick Emerson
www.sicapital.co.uk
Tel: 01483 413500
SPARK Advisory Partners Limited
Nominated Adviser
Matt Davis
www.Sparkadvisorypartners.com
Tel: 0203 368 3550

 

About Craven House Capital:

 

The Company's Investing Policy is to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets globally in any geographic jurisdiction. The company will invest in both developed and developing markets providing long term patient capital and is often involved in special situations, restructuring, expansion and turn around investments in crisis and transitioning economies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

MSCBLGDIDBXBGCG